Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 8/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 7/20 | 1.00 |
| ▸ | CSK | P41240 | 5/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 3/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.74 |
| ▸ | FES | P07332 | 1/20 | 0.67 |
| ▸ | FER | P16591 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284510 | 1.00 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284518 | 1.00 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL16786132 | 0.97 | MAPK14 (0.95) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL29496497 | 0.91 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284678 | 0.91 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284669 | 0.91 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL19986848 | 0.88 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL26882912 | 0.87 | MAPK14 (0.77) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL14704592 | 0.87 | MAPK14 (0.78) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL17515255 | 0.86 | DDR1 (0.95) | MAPK14MAP3K7MAP4K2MAP3K20CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | claimed |
| US-11590133-B2 | Methods and compositions for treatment of BRAF mutant cancers | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-02-28 | — | — | US | claimed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20250281607-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20250041303-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| CN-116271056-A | Cell death inducing agent for cell having BRAF gene mutation, proliferation inhibiting agent for the cell, and pharmaceutical composition for treating disease caused by abnormal proliferation of the cell | 日东电工株式会社 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023102379-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| WO-2023062115-A1 | METHODS FOR DETERMINING THE LIKELIHOOD OF A MALIGNANT DISEASE RESPONDING TO TREATMENT WITH A PHARMACEUTICAL INHIBITOR | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-04-20 | — | — | WO | disclosed |
| US-11590133-B2 | Methods and compositions for treatment of BRAF mutant cancers | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-02-28 | — | — | US | disclosed |
| WO-2023008462-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2023-02-02 | — | — | WO | disclosed |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2023-01-12 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| EP-4010081-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | MAPK14 1683/4885MAP3K7 1014/4885MAP4K2 1317/4885 |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | CDK9, KRAS, BRD9 | MAPK14 1827/4885MAP3K7 984/4885MAP4K2 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.